American Diabetes Association (ADA) 2023

Healthcare Utilization and Cost Associated with Empagliflozin in Older Adults with Type 2 Diabetes: Results from the EMPRISE Study

Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study

Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 RAs in Patients with Advanced CKD: Results from the EMPRISE study

Durable Improvement in HbA1c in Youth-Onset T2D: A Post Hoc Analysis of the DINAMO Trial

Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) stud

Utilization of Empagliflozin in Patients with Type 2 Diabetes Mellitus and Congestive Heart Failure